Cargando…

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors

The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2(nd) generation androgen receptor signaling inhibitors (ARSi) like Abiraterone Acetate (Abi) and Enzalutamide (Enza) or a functional driver o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yezi, Dalrymple, Susan L., Coleman, Ilsa, Zheng, S. Lilly, Xu, Jianfeng, Hooper, Jody E., Antonarakis, Emmanuel S., De Marzo, Angelo M., Meeker, Alan K., Nelson, Peter S., Isaacs, William B., Denmeade, Samuel R., Luo, Jun, Brennen, W. Nathaniel, Isaacs, John T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655549/ https://www.ncbi.nlm.nih.gov/pubmed/32989253 http://dx.doi.org/10.1038/s41388-020-01479-6

Ejemplares similares

Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
por: Brennen, W. Nathaniel, et al.
Publicado: (2021)

Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications
por: Zhao, Pei, et al.
Publicado: (2019)

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
por: Sena, Laura A., et al.
Publicado: (2022)

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer
por: Denmeade, Samuel R, et al.
Publicado: (2023)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling
por: D'Antonio, Jason M., et al.
Publicado: (2010)

Regulation of androgen receptor variants in prostate cancer
por: Zhu, Yezi, et al.
Publicado: (2020)

Bipolar androgen therapy (BAT): A patient's guide
por: Denmeade, Samuel, et al.
Publicado: (2022)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities
por: Basil, Paul, et al.
Publicado: (2022)

Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells
por: Wang, Shuaibin, et al.
Publicado: (2018)

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review
por: Sciarra, Alessandro, et al.
Publicado: (2019)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells
por: Shafi, Ayesha A., et al.
Publicado: (2015)

Quantification of Mesenchymal Stem Cells (MSCs) at Sites of Human Prostate Cancer
por: Brennen, W. Nathaniel, et al.
Publicado: (2012)

Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer
por: Akinboye, Emmanuel S., et al.
Publicado: (2019)

SUN-LB136 A Comparison of Androgen Receptor Splice Variant, AR-V7, and Glucocorticoid Receptor Activity in Prostate Cancer
por: Dash, Amit K, et al.
Publicado: (2020)

Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies
por: Ma, Yafeng, et al.
Publicado: (2016)

Expression of AR-V7 (Androgen Receptor Variant 7) Protein in Granular Cytoplasmic Structures Is an Independent Prognostic Factor in Prostate Cancer Patients
por: König, Paul, et al.
Publicado: (2020)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss
por: Markowski, Mark C., et al.
Publicado: (2022)

Immunohistochemical Expression of Androgen Receptors (AR) in Various Breast Cancer Subtypes
por: Ismael, Nour El Hoda S., et al.
Publicado: (2019)

Regulation of androgen receptor splice variant AR3 by PCGEM1
por: Zhang, Ziqiang, et al.
Publicado: (2016)

Mipsagargin: The Beginning—Not the End—of Thapsigargin Prodrug-Based Cancer Therapeutics
por: Isaacs, John T., et al.
Publicado: (2021)

Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex
por: Nyquist, Michael D., et al.
Publicado: (2023)

The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7
por: Stockley, Jacqueline, et al.
Publicado: (2015)

Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Rana, Manjul, et al.
Publicado: (2021)

α-Mangostin Promotes In Vitro and In Vivo Degradation of Androgen Receptor and AR-V7 Splice Variant in Prostate Cancer Cells
por: Nauman, Mirielle C., et al.
Publicado: (2023)

Androgen regulation of the androgen receptor coregulators
por: Urbanucci, Alfonso, et al.
Publicado: (2008)

Association of B7‐H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer
por: Mendes, Adrianna A., et al.
Publicado: (2022)

Androgen receptor (AR) antagonism triggers acute succinate‐mediated adaptive responses to reactivate AR signaling
por: Saxena, Neetu, et al.
Publicado: (2021)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
por: Zhang, Guanyi, et al.
Publicado: (2015)

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer
por: Narayanan, Ramesh, et al.
Publicado: (2017)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis
por: Khan, Tanzila, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_knhvha5qerdl5ag40bme3da811